Globant, a digitally native company, has partnered with MIT Technology Review Insights to launch a new report titled, ‘Transforming Commercial Pharma with Agentic AI.’ The report reveals that pharmaceutical companies are rapidly adopting AI agents across commercial and medical affairs, finding both strong momentum and clear priorities for the industry.
Key findings from the 250 senior executives surveyed globally, from the pharmaceuticals, Biotech and Bioengineering industries reveals:
- Nearly three quarters (73%) of respondents are planning, piloting or deploying agentic AI initiatives; some are already in production. Adoption is expected to climb sharply over the next 12–18 months.
- Regulatory compliance (51%), data standardisation (49%), patient support (46%) and market intelligence (46%) rank as the highest-priority use cases.
- Workflow design/orchestration (60%) and compliance/validation (55%) are the top challenges to deployment; tech infrastructure (42%) and data governance (38%) follow.
- Eight-four percent plan to prioritise data standardisation and integration to make agents reliable at scale.
The MIT Technology Review Insights team states that Generative AI is poised to create between US$60 billion and US$110 billion a year in economic value for the pharma and medical product industries, stating agentic AI could be the catalyst to kick-start a new phase of transformation for the sector.
To ensure that such promise is delivered, respondents are clear on the need for strong data foundations, with 84% ranking data standardisation and integration as a high or medium priority for enabling AI agents to deliver value.
Joaquín Labado, Healthcare and Life Sciences Managing Director at Globant, said: “AI agents can accelerate and innovate across the whole medical-marketing workflow, including research, strategy, execution and optimisation to create relevant and personalised content and services for a specific health care professional to engage with. Rather than create discomfort in a highly regulated industry, it’s a chance to set clear Agentic rules and guardrails that let us innovate at speed while staying compliant.”
